We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
176
Whitehawk Therapeutics
WHWK
$190M
$673K 0.03%
49,333
– –
RGNX icon
177
Regenxbio
RGNX
$620M
$658K 0.03%
+12,801
New +$639K
CBAY
178
DELISTED
Cymabay Therapeutics
CBAY
$631K 0.03%
+88,102
New +$998K
RARX
179
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$577K 0.02%
+19,190
New +$440K
MYGN icon
180
Myriad Genetics
MYGN
$270M
$571K 0.02%
20,549
– –
CLVS
181
DELISTED
Clovis Oncology, Inc.
CLVS
$561K 0.02%
37,700
-37,700
-50% -$681K
RYTM icon
182
Rhythm Pharmaceuticals
RYTM
$6.81B
$548K 0.02%
24,890
– –
CYH icon
183
Community Health Systems
CYH
$393M
$545K 0.02%
203,935
– –
FATE icon
184
Fate Therapeutics
FATE
$286M
$495K 0.02%
+24,379
New +$439K
CMRX
185
DELISTED
Chimerix, Inc.
CMRX
$494K 0.02%
+114,333
New +$352K
TTPH
186
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$413K 0.02%
42,966
– –
IMGN
187
DELISTED
Immunogen Inc
IMGN
$365K 0.01%
168,190
– –
MNK
188
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$303K 0.01%
32,980
– –
CAH icon
189
Cardinal Health
CAH
$53.9B
$297K 0.01%
6,300
– –
CDTX
190
DELISTED
Cidara Therapeutics
CDTX
$267K 0.01%
7,939
– –
ORKA
191
Oruka Therapeutics
ORKA
$5.82B
$264K 0.01%
3,006
-750
-20% -$67.3K
NVAX icon
192
Novavax
NVAX
$1.2B
$167K 0.01%
28,550
– –
CLSD
193
DELISTED
Clearside Biomedical
CLSD
$161K 0.01%
11,022
– –
TRIL
194
DELISTED
Trillium Therapeutics Inc.
TRIL
$146K 0.01%
446,099
– –
BLCM
195
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$102K ﹤0.01%
6,000
– –
QHC
196
DELISTED
Quorum Health Corporation
QHC
$33K ﹤0.01%
23,725
– –
CLDX icon
197
Celldex Therapeutics
CLDX
$2.99B
$19K ﹤0.01%
7,053
– –
AKBA icon
198
Akebia Therapeutics
AKBA
$354M
– –
-213,942
Closed -$1.75M
CNC icon
199
Centene
CNC
$30.7B
– –
-128,295
Closed -$6.81M
DNLI icon
200
Denali Therapeutics
DNLI
$3.65B
– –
-19,372
Closed -$450K
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.